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Abstract. Purpose: The aim of this study was to analyse
the impact of FDG-PET staging on treatment results of
neo-adjuvant radiochemotherapy in patients with ad-
vanced non-small cell lung cancer (NSCLC). We com-
pared prospectively the outcome of two patient groups
with stage III NSCLC undergoing the same neo-adjuvant
radio-chemotherapy (NARCT). In one group, FDG-PET
was part of the pretherapeutic staging, whereas in the other
group, no PET scans were performed.
Methods: One hundred and eighty-eight patients with
advanced stage III NSCLC were selected for a phase II
trial of NARCT. The first 115 patients underwent
conventional workup (CWU) and FDG-PET before inclu-
sion (group I); the remaining 73 patients underwent CWU
only (group II). All patients were followed up according to
a standardised protocol for at least 11 months (up to 64
months). Overall survival and disease-free survival were
used as parameters of therapeutic success and analysed
statistically.
Results: After staging, 157/188 patients were included in
the clinical trial. Thirty-one were excluded owing to the
results of FDG-PET, in most cases because of the
detection of previously unknown distant metastases.
Overall survival and metastasis-free survival were sig-
nificantly longer in patients of group I stratified by FDG-
PET than in group II (p=0.006 and 0.02 respectively).
Another significant factor for survival was complete
tumour resection (p=0.02). Gender, histological tumour
type, tumour grade and UICC stage had no significant
influence.
Conclusion: Pretherapeutic staging by FDG-PET signifi-
cantly influences the results of NARCT and subsequent
surgery by identifying patients not eligible for curative
treatment.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer death in both men and women. Patients with
stage I or II NSCLC may be cured by surgery, whereas
those with stage IIIA or IIIB are considered inoperable. In
the past the only therapeutic option for these patients was
radiotherapy and/or palliative chemotherapy. Recently a
new therapeutic strategy was introduced, aiming at tumour
reduction in order to reach an operable tumour stage. Since
then, several new agents and many different regimens
consisting of various combinations of chemotherapy and
radiotherapy have been studied in large clinical trials [1–5].
The PLUS study [6], a randomised study by van
Tinteren et al., demonstrated that
18F-fluorodeoxyglucose
positron emission tomography (FDG-PET) has the poten-
tial to avoid futile surgery in patients with advanced
NSCLC. In accordance with other studies [7–15], the
authors demonstrated superior diagnostic accuracy of
FDG-PET staging prior to surgery as compared with the
standard staging procedures [computed tomography (CT)
of thorax and chest, ultrasonography of the abdomen, bone
scintigraphy and mediastinoscopy]. PET staging revealed
previously unknown M1 or N3 stage in about 30% of all
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The PLUS study confirmed that FDG-PET is suitable for
selection of those patients who will profit from aggressive
treatment regimens. Therefore it can be assumed that
improved patient selection might lead to better results, in
particular longer survival in patients undergoing aggressive
treatment.
Nosuchoutcomedataareasyetavailable.Arecentstudy
by Hoekstra et al. analysed the prognostic relevance of
response evaluationusingFDG-PETin 47patients [16].Her
groupwas abletoshow thatcertain FDG-PET findings prior
to and after neoadjuvant therapy were highly predictive for
patient outcome. However, no direct comparison of treat-
ment results for patients staged by PET and those staged
without use of PET has been published to date. The aim of
the presented prospective study was therefore to find out
whether patients with advanced NSCLC (IIIA or IIIB)
staged by FDG-PET have an improved clinical outcome
compared with those staged by conventional procedures
only, when the same treatment protocol was employed.
Materials and methods
Patients
An overview of our study population, including the results of
surgery and clinical follow-up, is given in Fig. 1. From August
1998 to March 2004, 188 consecutive patients with histologically
proven NSCLC were selected for inclusion in a neo-adjuvant
phase II trial [17]. Inclusion criteria were as follows: NSCLC of
UICC stage III, age between 18 and 70 years, presence of
macroscopic tumour manifestations. Patients in poor condition
(Karnofsky index <70%) were excluded, as were patients with
supraclavicular lymph node or distant metastases (stage IV)
shown by conventional workup (CWU) and patients who had
previously been treated because of other malignant diseases. The
study was approved by the local ethics committee; all patients
gave informed consent to participation.
One hundred and fifty-seven of the patients (121 male, 36
female, mean age 57.9 years, range 31–70 years) were finally
enrolled in the study. Whether or not a patient received FDG-PET
depended solely on the time of inclusion: between August 1998
amd January 2002, patients selected for radiochemotherapy were
routinely referred for FDG-PET (group I: CWU+PET, n=115).
After January 2002, FDG-PET was no longer part of the routine
staging protocol for budgetary reasons (group II: CWU only,
n=73).
All patients underwent the same neoadjuvant treatment proto-
col: Induction chemotherapy (weeks 0–4) consisted of 100 mg/m
2
paclitaxel (Taxol) and carboplatin (Carboplat) per infusion applied
weekly, followed by a second treatment cycle (weeks 6–9)
consistingof radiotherapy(2×1.5Gy/day, 5×/week upto 45Gy) in
combination with paclitaxel (50 mg/m
2) and carboplatin [area
under the curve (AUC) 2] on days 1, 8 and 15 of radiation.
Routine staging
CWU consisted of bronchoscopy with biopsy, X-ray and CTof the
chest, mediastinoscopy, bone scintigraphy, and ultrasonography or
CT of the abdomen. Patients were assigned to stage IIIA or IIIB
according to the system developed by the American Joint
Committee on Cancer [18].
FDG-PET
As part of the staging procedure in patient group I, FDG-PETwas
performed after conventional staging, but prior to mediastinos-
copy to avoid secondary (postoperative) changes. A whole-body
PET scanner (Advance, General Electric Medical Systems,
Milwaukee, WI, USA) operated in 2D mode was used for all
PET scans. After a 12-h overnight fast, patients were injected
Fig. 1. Trial profile. Fourteen
patients were lost to follow-up,
comprising eight who refused
to participate in further
follow-up and six who moved
away from the area
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18F-FDG intravenously. Blood glucose levels
were lower than 6.7mmol/l in all patients (mean5.2±1.3 mmol/l).
One hour after injection, static emission scans were obtained
covering the neck, thorax, abdomen and pelvis (six fields of
view=90 cm). PET scans were processed using iterative recon-
struction, and images were corrected for attenuation. FDG uptake
was calculated as average SUV (standardised uptake value,
SUVavg) derived from regions of interest using an isocontour
threshold defined as: threshold=(SUVmax+SUVbackground)/2.
Image analysis was done by two experienced nuclear medicine
specialists who evaluated the extent of the primary tumour,
mediastinal lymph node spread and presence of distant metas-
tases (S.M.E., M.R.), without being aware of the other results of
conventional staging. For assessment of mediastinal foci, a SUV
cut-off of 2.5 was applied to discriminate between benign (<2.5)
and malignant (>2.5) lesions.
Surgery
The decision to perform surgery was based on local findings of
CT and re-mediastinoscopy or video thoracoscopy after comple-
tion of neoadjuvant therapy. Results of pretherapeutic staging
PET were integrated whenever distant metastases identified by
PET could be verified by another imaging method. “Successful
surgery” was defined as complete resection of all visible or
previously detected tumour parts, including corresponding
mediastinal lymph node stations. “No or no successful surgery”
was defined asfailure to perform an operation owingto the results
of post-therapeutic re-staging or because intraoperative findings
of exploratory thoracotomy indicated an inoperable situation.
Outcome analysis
Standardised follow-up of all patients (physical and laboratory
examinations, repeated CT or X-ray of the chest at 3-monthly
intervals; detailed follow-up protocols for the period of radio-
chemotherapy and after surgery have been published previously
[19]) was organised by the Schillerhoehe Hospital as the
responsible study centre. A last update was obtained in
November 2005.
Statistical analysis
The Kaplan-Meier method was used to estimate the survival
probability for groups I and II. Survival time was defined as the
time between tumour verification by histology and death or last
follow-up. Disease-free survival was defined as the interval
between surgery and onset of local recurrence or detection of
distant metastases. The relationship between PET staging and
survival was tested by the log-rank test. Univariate Cox analysis
was applied to assess the effects of the following variables on
survival: age, gender, histological tumour type, tumour grade and
tumour stage. Interactions and joint effects of the variables “PET
staging” and “successful operation” were examined in a Cox
proportional hazards model.
Results
Patients
From August 1998 to March 2004 a total of 188 patients
with suspected stage III NSCLC were assessed for
eligibility for neoadjuvant treatment; as indicated
above,115 of them underwent CWU and FDG-PET,
while 73 only conventional workup (Fig. 1).
Thirty-one patients of group I (27%) were excluded
from neoadjuvant treatment after FDG-PET. In 28 of these
patients (24%), PET detected distant metastases and these
cases were thus UICC stage IV. Three further patients were
excluded owing to absence of tumour (n=2) or change in
histological diagnosis (n=1). In the latter case an atypical
pattern found at FDG-PET (mediastinal bulk without
localised lung lesion) initiated histological re-evaluation,
which finally revealed seminoma instead of NSCLC. Thus,
in total 157 patients were included in this analysis, 84
belonging to group I (PET staging) and 73 to group II
(CWU). Of the 28 patients with distant metastases shown
by PET, ten nevertheless received neoadjuvant treatment
because metastases could not yet be identified by other
methods at that time point (n=8) or because surgical
resection of adrenal metastases was planned (n=2).
Survival of those patients with distant metastases was not
taken into account.
Surgery was performed in 103/157 patients, including
59/84 (69%) in group I and 44/73 (60%) in group II.
Complete tumour resection could be achieved in 48 of
group I (57%) and 37 of group II (51%) (Table 1). Nine
patients died postoperatively, corresponding to an in-
hospital operative mortality of 8.7%.
Comparison of groups I and II
The two patient groups were compared statistically with
regard to other factors which might have an influence on
outcome: age, gender, tumour stage, T stage assessed by
CT and N stage assessed by mediastinoscopy. Results are
shown in Table 1. The groups showed a significant
difference with regard to tumour stage. No other significant
differences could be identified.
Univariate survival analysis
Follow-up data were available for all 157 patients. One
hundred and three patients had died. Of the remaining 54
patients, 40 are alive at present (November 2005). No
recent follow-up data are available in 14 patients owing to
refusal of further follow-up (n=8) or the patient moving
away from the area (n=6). The median overall survival of
the whole patient group was 14.2 months (group I, 22.3
months vs group II, 11.3 months). The median follow-up of
the 40 patients who are still alive is 35.3 months [16–50.6
months (25–75% quantiles)] in group I and 16.4 (8.4–22.4)
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concerning the following criteria: staging by PET,
complete tumour resection, UICC stage, N stage, T stage,
histological tumour type, age and gender. Outcome in
terms of overall survival (Fig. 2, p=0.006) or time interval
until onset of distant metastases (Fig. 3, p=0.02) was
significantly better in patients of group I. Distant metastases
occurred in 61 patients during follow-up: 22 patients devel-
oped brain metastases, 17 bone metastases, seven liver
metastases, six lung metastases, four adrenal metastases,
three abdominal metastases and two cervical metastases.
The interval until the onset of local recurrence in
patients who underwent surgery was not significantly
different between the two groups (p=0.6).
Complete resection led to a significantly better outcome
in the whole patient group (p=0.02). The influence of
UICC stage was not significant: patients with stage IIIA
had only a slightly better outcome (p=0.2). Survival was
not significantly affected by age, gender, N stage as
determined by mediastinoscopy, T stage as determined by
CT, histological tumour type or tumour grade.
Multivariate survival analysis
Interactions and joint effects of the variables “PETstaging”
and “successful operation” were examined in a Cox
proportional hazards model. The only variable significantly
correlated with survival in all subgroups was staging by
PET. An interesting additional result of subgroup analysis
was a highly significant difference between the patients
who underwent resection after PET staging versus patients
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Fig. 2. Kaplan-Meier survival analysis: overall survival. Patients are
grouped according to whether they underwent PETand conventional
workup (CWU) (group I, n=84) or CWU only (group II, n=73).
Patients included on the basis of additional PET staging survived
significantly longer (p=0.006)
Table 1. Description of groups I (CWU and FDG-PET) and II (CWU without FDG-PET)
All patients (n=157) Group I: CWU+PET (n=84) Group II: CWU only (n=73) p value
Age (yrs) Mean SD Mean SD Mean SD
57.88 7.69 57.15 7.78 58.7 7.55 0.21
Gender n % n % n % 0.47
Male 121 77% 65 77% 56 77%
Female 36 23% 19 23% 17 23%
Tumour stage n % n % n % 0.006
IIIA 47 30% 33 38% 14 19%
IIIB 110 70% 51 62% 59 81%
N stage (med.) n % n % n % 0.65*
N0-1 44 28% 20 24% 24 33%
N2 76 48% 43 51% 33 45%
N3 37 24% 21 25% 16 22%
T stage (CT) n % n % n % 0.16**
T1 9 6% 4 5% 5 7%
T2 35 22% 18 21% 17 23%
T3 30 19% 22 26% 8 11%
T4 83 53% 40 48% 43 59%
Surgery n % n % n % 0.42
No surgery 54 34.4% 25 30% 29 39.7%
Exploratory only 18 11.5% 11 13% 7 9.6%
Lobectomy 35 22.3% 17 20% 18 24.7%
Bilobectomy 4 2.5% 2 2% 2 2.7%
Pneumonectomy 46 29.3% 29 35% 17 23.3%
No complete resection 72 46% 36 43% 36 49%
Complete resection 85 54% 48 57% 37 51%
med. mediastinoscopy
*N0–2 vs N3, **T1–3v sT 4
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p=0.002).
Discussion
Prognosis and survival in non-small cell lung cancer
(NSCLC) are mainly determined by two factors: the local
resectability of the tumour and the presence of systemic
tumour spread. For operable stages (no contralateral lymph
node metastases, T1–3, no distant metastases), a 5-year
disease-free survival of up to 60% has been reported [20].
Nowadays, in primary, inoperable NSCLC (stage IIIA
and B), new neoadjuvant treatment protocols, consisting
of combined chemotherapy and radiation, have been devel-
opedwiththeaimofreducingtumourextentinordertoreach
anoperablestage.Thesetherapeuticregimensareaggressive
andunderpermanentclinicalevaluation.Thisstudywaspart
of an ongoing phase II trial for the evaluation of a new
neoadjuvant radiochemotherapy protocol [17]. In the first
part of the study, PET staging was prescribed in addition to
conventionalworkupwiththeaimofevaluatingtheaccuracy
of PETstaging. After inclusion of 115 patients, the trial was
prolonged,butwithoutFDG-PET.Inthefirstpartofthetrial,
PET detecteddistant metastases in 24%of the patients. After
NARCT, a comparable proportion of patients remained
inoperable in both groups (45% vs 49%). This reflects the
fact that pretherapeutic PET is of limited value for the
assessment of local resectability because it does not show
the exact tumour extent or infiltration of neighbouring
structures. Accordingly, local recurrences occurred with
similarfrequenciesinbothgroups.Incontrast,thefrequency
of new distant metastases during ongoing NARCTand after
NARCT was significantly higher in patients who were not
staged by PET (p=0.02, mean time to onset of metastases:
2.7yearsingroupIvs1.0yearsingroupII).Astotheoverall
survival, we were able to demonstrate that patients selected
for NARCT by PET staging had a highly significant longer
survival than those who underwent conventional workup
only. This survival advantage presumably is not based on
improved local tumour control but rather on a lower
frequency and later onset of distant metastases. An
interesting and surprising result was that even when patients
with distant metastases were included in the analysis,
patients staged by PETstill had a better outcome. Of course,
this finding has to be interpreted with care, since patient
inclusion was not randomised and this result may reflect a
difference in characteristics between the two groups even
when it was not significantly detectable in univariate
analysis. One explanation for this finding might be the
advantage of avoiding unnecessary and aggressive therapy,
taking into account the high morbidity and mortality of
extensive surgery and intense radiation and chemotherapy:
in our study group, in 9/188 patients death was caused by
surgery or postoperative morbidity and in four further
patients by radiotherapy.
We are aware that one limitation of this study is that it
was not initially designed for the evaluation of PET
staging. The primary endpoint was the assessment of the
new neoadjuvant treatment. Thus, the data are prospective,
but not randomised as to the performance of FDG-PET.
The two groups are quite comparable concerning demo-
graphic data, T and N stage, and pretherapeutic lung
function. Only the UICC stage is significantly different,
which nonetheless turned out to have no significant
influence on overall survival. A second limitation is that
the follow-up in the second group is considerably shorter
because of later patient inclusion. However, we found this
difference irrelevant, because at the time of the last follow-
up more than half of the patients were already dead in both
groups. On the other hand, it is a strength of this study that
the clinical setting was strictly standardised in many
respects: All patients underwent the same staging (X-ray
and CTof the thorax, bronchoscopy, ultrasonography, bone
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Fig. 3. Kaplan-Meier analysis: time interval until onset of distant
metastases. Patients are grouped according to whether they under-
went PET and conventional workup (CWU) (group I, n=84) or
CWU only (group II, n=73). The time interval to onset of metastases
was significantly longer in group I (p=0.02)
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Fig. 4. Subgroup analysis: survival in patients who underwent
successful operation, grouped by staging by PET (group I, n=48)
and conventional staging only (group II, n=37). There was a highly
significant difference between patients staged by PET and those
conventionally staged (p=0.002)
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completed in one group by the addition of FDG-PET
staging. We included only patients with UICC stage IIIA
and B. All patients were selected for a phase II trial with a
neoadjuvant treatment protocol consisting of a combina-
tion of paclitaxel and carboplatin, followed by hyperfrac-
tionated radiotherapy and, in the event of a favourable
response, curative surgery. Mediastinoscopy and surgery
were performed by the same physicians, as was the follow-
up, and all PET investigations were performed on the same
scanner by the same two physicians. So, inter-observer
variability and influence of different therapeutic ap-
proaches did not play a role in the results.
Some aspects of the value of PET staging for patient
selection for neoadjuvant therapy remain unclear. FDG-
PET was performed in addition to all established conven-
tional staging procedures. A question to be addressed by
future controlled studies could be whether it is possible to
replace one or more diagnostic procedures (for example,
bone scintigraphy or mediastinoscopy in patients with
negative PET findings in the mediastinum) without loss of
diagnostic accuracy.
Conclusion
We conclude from this study that FDG-PET staging
contributes to optimal treatment planning in patients with
UICC stage III NSCLC by identifying patients with
previously unknown N3 and M1 stage disease that
warrants exclusion from unnecessary radiochemotherapy
as well as from surgery. This patient selection results in
improved outcome despite the fact that it does not improve
local tumour control by surgery. It appears to be justified in
order to restrict aggressive neoadjuvant treatment to
patients who will presumably benefit from the procedure.
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